Introduction {#sec1_1}
============

Polypharmacy is an emerging concern because of its associations with falls, adverse drug events, frailty, hospitalization, and mortality \[[@B1]\]. A recent systematic review found that polypharmacy was related to cognitive impairment in community-dwelling older adults \[[@B2]\].

Patients with Parkinson\'s disease (PD) are well-known to develop dementia; a prior study showed that 15--20′ of patients with newly diagnosed PD had minimal cognitive impairment (MCI), and 80′ of patients with PD were diagnosed with dementia 20 years after disease onset \[[@B3]\]. MCI is a risk factor for the development of dementia in patients with PD \[[@B4]\]; thus, effective interventions for MCI in the early stages of PD might prevent the progression of dementia. Medication reduction to avoid polypharmacy is a potential intervention for improvement of cognitive function; however, it remains unknown whether polypharmacy affects cognitive function in patients with newly diagnosed PD. Here, in a cross-sectional study of patients with newly diagnosed PD, we evaluate the association between polypharmacy and cognitive function, as measured with the Mini-Mental State Examination (MMSE) \[[@B5]\].

Materials and Methods {#sec1_2}
=====================

Patients {#sec2_1}
--------

During the period from April 2012 to March 2019, consecutive hospitalized patients who were newly diagnosed with PD at the University of Miyazaki Hospital were enrolled into this cross-sectional study. All of the patients were diagnosed with clinically established or clinically probable PD in accordance with International Parkinson and Movement Disorder Society clinical diagnostic criteria \[[@B6]\]. We excluded patients who could not perform activities of daily living or function independently due to cognitive impairment. Patients were classified into 2 groups according to the presence or absence of polypharmacy, which was defined as treatment with 6 or more medications \[[@B7]\]. The study protocol was approved by the Ethics Committee of the University of Miyazaki. Written informed consent was obtained from all of the participants.

Variables {#sec2_2}
---------

We retrospectively collected the following clinical history, comorbidities, and findings associated with PD at the time of diagnosis: MMSE score, age, sex, years of education, history of alcohol intake, smoking, dyslipidemia, diabetes, hypertension, ischemic heart disease, stroke, motor subtype (tremor-dominant, akinetic-rigid, or mixed type) \[[@B8]\], presence of a depressive state, orthostatic hypotension, olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD), Hoehn and Yahr scale \[[@B9]\], and disease duration. Orthostatic hypotension was defined as a reduction of at least 20 mm Hg in systolic and/or 10 mm Hg in diastolic blood pressure within 3 min of standing \[[@B10]\]. We assessed the presence or absence of symptoms of a depressive state, olfactory dysfunction, and RBD by direct interviews with patients and their families. Years of education were classified as follows, based on the Japanese educational system: 0--9 years, junior high school; 10--12 years, high school; and ≥13 years, post-high school education \[[@B7]\].

Statistical Analysis {#sec2_3}
--------------------

The *t* test was used to compare continuous variables, while the χ^2^ test was used to compare categorical variables. Univariable analyses were conducted in the unadjusted patient groups (nonpolypharmacy vs. polypharmacy). The method of inverse probability weighting (IPW) with a propensity score was used to minimize confounding biases. First, a propensity score was constructed using all of the following baseline characteristics (the MMSE score was excluded): age, sex, years of education, social history (alcohol drinking habits and smoking), medical history (hypertension, diabetes, dyslipidemia, ischemic heart disease, and stroke), clinical characteristics of PD (disease duration, motor subtype, Hoehn and Yahr scale, depression, orthostatic hypotension, olfactory dysfunction, and rapid eye movement sleep behavior disorder). IPW with propensity scores was then performed to adjust different covariate distributions for both groups; analyses were then conducted with these IPW-adjusted groups. Statistical analyses were conducted with R software (version 3.5.1; R Foundation for Statistical Computing, Vienna, Austria), and *p* \< 0.05 was considered statistically significant.

Results {#sec1_3}
=======

Table [1](#T1){ref-type="table"} shows the baseline characteristics of the included patients at the time of diagnosis with PD. One hundred thirty-one patients were enrolled into this study. The mean age was 69.8 ± 8.2 years, and 61 patients (46.6′) were men; 43 patients (32.8′) met the criteria for polypharmacy. Univariable analysis using unadjusted patient groups demonstrated significant differences in the following factors: MMSE score, age, years of education, history of hypertension, history of ischemic heart disease, and presence of RBD. The propensity score constructed from the 17 baseline characteristics corresponded well with the data, which showed a receiver operating characteristic curve with a c-statistic of 0.89. Despite the use of IPW to adjust for confounders, patients in the polypharmacy group continued to exhibit a significantly lower average MMSE score than that of patients in the nonpolypharmacy group (26.2 vs. 27.7, *p* = 0.001; Table [2](#T2){ref-type="table"}).

Discussion {#sec1_4}
==========

In the present study, we found that patients with newly diagnosed PD who met the criteria for polypharmacy had significantly lower MMSE scores than patients who did not meet the criteria for polypharmacy. After IPW adjustment, patients who met the criteria for polypharmacy had an average MMSE score of 26.2, which was −1.5 points lower than that of patients who did not meet the criteria for polypharmacy.

Previous studies have assessed the association between polypharmacy and dementia in community-dwelling older adults \[[@B2]\] and found that community-dwelling elderly people who met the criteria for polypharmacy had an average MMSE score that was 0.51 points below that of elderly people who did not meet the criteria for polypharmacy \[[@B11]\]; the difference in MMSE score was greater in our newly diagnosed PD cohort. We speculate that polypharmacy may exhibit a greater effect on the cognitive function of patients with newly diagnosed PD, compared to community-dwelling elderly people, for the following reasons. Generally, people with a relative cerebral functional decline, including older adults or patients with dementia, are likely to develop medication-induced neuropsychiatric symptoms, such as delirium \[[@B12]\]. Indeed, patients with newly diagnosed PD showed reduced cerebral glucose metabolism and cognitive function \[[@B13]\], and 15--20′ of such patients demonstrated MCI \[[@B3]\]. Thus, the combination of polypharmacy with aging and subclinical cerebral dysfunction due to PD pathology may have a greater effect on the cognitive function of patients with newly diagnosed PD compared to community-dwelling elderly people.

We suspect that medication reduction may improve cognitive function in patients with newly diagnosed PD. Some predictive factors for the development of dementia in patients with PD include autonomic dysfunction, RBD, and MCI \[[@B4]\]. Indeed, the median score of MMSE in our patients who met the criteria for polypharmacy was \<27, which was used as the cut-off value for MCI in a previous study \[[@B14]\]; conversely, patients in the present study who did not meet the criteria for polypharmacy had an MMSE score above the cut-off level. Thus, medication reduction might be a means to prevent dementia if it is confirmed to improve cognitive function.

However, the relationship between medication reduction and improved cognitive function is controversial. A previous systematic review found that medication reduction in a general practitioner or family physician setting did not affect clinical outcomes, including cognitive function \[[@B15]\]. In contrast, a study of patients with late-stage PD showed that patients with levodopa-carbidopa intestinal gel infusion therapy (Duodopa®) had better cognitive function than patients in the polypharmacy group \[[@B16]\]. Medication reduction might have a positive impact on cognitive function in patients with PD. Further studies are needed to confirm this hypothesis in patients with newly diagnosed PD.

There were a few notable limitations in this study. First, this was a cross-sectional study; thus, a few patients with newly diagnosed PD might have later been diagnosed with atypical parkinsonism, such as progressive supranuclear palsy, multiple system atrophy, or corticobasal degeneration. Second, we analyzed the effect of the number of medications without specifically controlling for the use of medications that affect the central nervous system (e.g., benzodiazepines and anticholinergic drugs).

In conclusion, we demonstrated that patients with newly diagnosed PD who met the criteria for polypharmacy had lower cognitive function than patients who did not meet the criteria for polypharmacy. This is the first study to demonstrate an association between polypharmacy and cognitive decline in patients with newly diagnosed PD, as well as in community-dwelling older adults. Medication reduction might be a promising intervention to prevent the development of dementia in patients with early PD. Further prospective studies are needed to confirm whether medication reduction in patients with newly diagnosed PD can improve cognitive function and prevent the development of dementia.
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###### 

Clinical characteristics of patients with and without polypharmacy

                              Total (*n* = 131)   Polypharmacy               
  --------------------------- ------------------- -------------- ----------- ---------
  MMSE score                  27.1±2.6            27.8±2.6       25.8±2.3    \<0.001
  Age, years                  69.8±8.2            67.7±7.9       74.3±6.9    \<0.001
  Males                       61 (46.6)           41 (46.6)      20 (46.5)   1.00
  Education                                                                  
   0--9 years                 46 (35.1)           23 (26.1)      23 (53.5)   0.008
   10--12 years               59 (45.0)           46 (52.3)      13 (30.2)   
   ≥13 years                  26 (19.8)           19 (21.6)      7 (16.3)    
  Social history                                                             
   Alcohol drinking habits    41 (31.3)           27 (30.7)      14 (32.6)   0.99
   Smoking                    24 (18.3)           14 (15.9)      10 (23.3)   0.44
  Medical history                                                            
   Hypertension               60 (45.8)           31 (35.2)      29 (67.4)   0.001
   Diabetes                   19 (14.5)           11 (12.5)      8 (18.6)    0.50
   Dyslipidemia               28 (21.4)           16 (18.2)      12 (27.9)   0.30
   IHD                        6 (4.6)             1 (1.1)        5 (11.6)    0.02
   Stroke                     8 (6.1)             4 (4.5)        4 (9.3)     0.50
  PD                                                                         
   Disease duration, months   20.2±14.7           19.7±14.7      21.1±14.7   0.62
   Motor subtype                                                             
    Tremor-dominant           40 (30.5)           30 (34.1)      10 (23.3)   0.25
    Akinetic-rigid            78 (49.5)           48 (54.5)      30 (69.8)   
    Mixed                     13 (9.9)            10 (11.4)      3 (7.0)     
   Hohen and Yahr scale                                                      
    1                         23 (17.6)           17 (19.3)      6 (14.0)    0.08
    2                         58 (44.3)           43 (48.9)      15 (34.9)   
    3                         39 (29.8)           24 (27.3)      15 (34.9)   
    4                         9 (6.9)             4 (4.5)        5 (11.6)    
    5                         2 (1.5)             0 (0)          2 (4.7)     
   Depressive state           19 (14.5)           14 (15.9)      5 (11.6)    0.70
   Orthostatic hypotension    39 (29.8)           28 (31.8)      11 (25.6)   0.60
   Olfactory dysfunction      41 (31.3)           30 (34.1)      11 (25.6)   0.43
   RBD                        67 (51.1)           39 (44.3)      28 (65.1)   0.04

Values are presented as means ± SD or numbers (%). IHD, ischemic heart disease.

###### 

MMSE score of the unadjusted and IPW-adjusted groups

  Group          Unadjusted groups   IPW-adjusted groups                                
  -------------- ------------------- --------------------- --------- ------- ---------- -------
  Polypharmacy                                                                          
   No            88                  27.8±2.6              \<0.001   123.5   27.7±2.6   0.001
   Yes           43                  25.8±2.3                        108.7   26.2±2.0   

Values are presented as means ± SD or numbers. The following confounders were adjusted for IPW with propensity scores: age, sex, years of education, social history (alcohol drinking habits and smoking), medical history (hypertension, diabetes, dyslipidemia, ischemic heart disease, and stroke), clinical characteristics of PD (disease duration, motor subtype, Hohen and Yahr scale, depression, orthostatic hypotension, olfactory dysfunction, and RBD).
